BAP1 and mesothelioma: MiST is an open-label parallel-arm phase 2 trial which explored the efficacy of rucaparib, a PARP inhibitor, in patients with PM with BAP1-deficient or BRCA1-deficient mesothelioma pretreated with chemotherapy.